🧬 New NEJM data on Olezarsen!
In patients with severe hypertriglyceridemia, monthly RNA-targeted therapy delivered major triglyceride reductions (−62% to −72%) and a significant drop in acute pancreatitis risk (rate ratio 0.15).
✨ Improvements extended to ApoC-III, remnant cholesterol, and non-HDL cholesterol, with consistent benefits across both CORE-TIMI trials.
💡 A promising step forward in precision lipid therapy and pancreatitis prevention.
